The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

Fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds can be utilized as lipid droplet (LD)-specific bio-probes in cell imaging, with high photostability and brightness. For example, the compounds can be used for specific two-photon LDs staining in live cells and deep-tissues at ultralow concentrations. The compounds exhibit a large Stokes shift (>110 nm), high solid fluorescence quantum yields (up to 0.30), a good two-photon absorption cross-section (45-100 GM at 860 nm), high biocompatibility, and good photostability.

Fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds can be utilized as lipid droplet (LD)-specific bio-probes in cell imaging, with high photostability and brightness. For example, the compounds can be used for specific two-photon LDs staining in live cells and deep-tissues at ultralow concentrations. The compounds exhibit a large Stokes shift (>110 nm), high solid fluorescence quantum yields (up to 0.30), a good two-photon absorption cross-section (45-100 GM at 860 nm), high biocompatibility, and good photostability.

The present invention relates to a novel cathode buffer layer material and an organic photoelectric device including the same. When the novel compound of the present invention is applied to a cathode buffer layer of an organic photoelectric device, for example, an organic solar cell or an organic photodiode, there is an effect in which the surface characteristics of an electron transport layer are improved through the high dipole moment of the novel compound to thereby facilitate electron extraction from a photoactive layer to a cathode electrode and to reduce series resistance and leakage current, and accordingly, the performance of an organic optoelectronic device (organic solar cell, organic photodiode, etc.) to be manufactured can be remarkably improved, which is industrially advantageous.

The present invention relates to a novel cathode buffer layer material and an organic photoelectric device including the same. When the novel compound of the present invention is applied to a cathode buffer layer of an organic photoelectric device, for example, an organic solar cell or an organic photodiode, there is an effect in which the surface characteristics of an electron transport layer are improved through the high dipole moment of the novel compound to thereby facilitate electron extraction from a photoactive layer to a cathode electrode and to reduce series resistance and leakage current, and accordingly, the performance of an organic optoelectronic device (organic solar cell, organic photodiode, etc.) to be manufactured can be remarkably improved, which is industrially advantageous.

A nitrile oxide compound which is a compound represented by General Formula [I], in which a melting point is 25 C. to 300 C., and an equivalent of nitrile oxide is 1.0 to 4.5 mmol/g.

##STR00001##

In the general formula, s: an integer of 1 to 4; R.sup.1 and R.sup.2: a hydrocarbon group having 4 to 10 carbon atoms or a halogenated hydrocarbon group having 4 to 10 carbon atoms; X: a divalent hydrocarbon group, O, S, or N(R.sup.3); R.sup.3: a hydrogen atom or a hydrocarbon group having 1 to 6 carbon atoms; and A: an s-valent organic group.

A nitrile oxide compound which is a compound represented by General Formula [I], in which a melting point is 25 C. to 300 C., and an equivalent of nitrile oxide is 1.0 to 4.5 mmol/g.

##STR00001##

In the general formula, s: an integer of 1 to 4; R.sup.1 and R.sup.2: a hydrocarbon group having 4 to 10 carbon atoms or a halogenated hydrocarbon group having 4 to 10 carbon atoms; X: a divalent hydrocarbon group, O, S, or N(R.sup.3); R.sup.3: a hydrogen atom or a hydrocarbon group having 1 to 6 carbon atoms; and A: an s-valent organic group.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.